CPT® Code 38228

1. Indications

The indications for administering Chimeric antigen receptor T-cell (CAR-T) therapy, specifically CPT® Code 38228, include the treatment of certain types of cancers where traditional therapies have been ineffective. This therapy is particularly indicated for patients with:

• Acute Lymphoblastic Leukemia (ALL) - A type of cancer that affects the blood and bone marrow, characterized by the overproduction of immature lymphocytes.
• Large B-cell Lymphoma - A fast-growing form of non-Hodgkin lymphoma that arises from B-cells, which are a type of white blood cell.
• Chronic Lymphocytic Leukemia (CLL) - A slow-growing cancer of the blood and bone marrow that affects lymphocytes.

2. Procedure

The procedure for Chimeric antigen receptor T-cell (CAR-T) therapy involves several critical steps that ensure the effective modification and administration of the patient's T-cells. Each step is essential for the successful outcome of the therapy.

• Step 1: Blood Collection - The initial step involves the withdrawal of blood from the patient, which may occur over one or more days. This process is crucial as it allows for the collection of T-lymphocytes, which are the target cells for genetic modification.
• Step 2: T-Cell Isolation - After blood collection, the T-lymphocytes are separated from the other components of the blood. This isolation is performed using specialized techniques to ensure that a sufficient quantity of T-cells is available for the next steps.
• Step 3: Genetic Modification - The isolated T-lymphocytes are then taken to a laboratory or manufacturing facility where they undergo genetic engineering. An inactive virus is introduced into the T-cells, which carries the genetic instructions for producing chimeric antigen receptors (CARs) on the surface of the T-cells.
• Step 4: Expansion of CAR-T Cells - Following genetic modification, the CAR-T cells are expanded and multiplied in the laboratory until they reach a target quantity, often in the hundreds of millions. This step is vital to ensure that there are enough modified T-cells to effectively target and destroy cancer cells.
• Step 5: Lymphodepleting Chemotherapy - While the CAR-T cells are being manufactured, the patient receives lymphocytic cell-depleting chemotherapy. This treatment helps to reduce the number of existing lymphocytes in the patient’s body, creating a more favorable environment for the infused CAR-T cells to thrive and function.
• Step 6: Infusion of CAR-T Cells - Once the CAR-T cells are ready and the patient has completed the preparatory chemotherapy, the final step is the infusion of the engineered CAR-T cells back into the patient. This infusion allows the CAR-T cells to enter the bloodstream, where they can seek out and attach to cancer cells, initiating their destruction.

3. Post-Procedure

After the administration of CAR-T cells, patients are monitored closely for any potential side effects or complications. Common post-procedure care includes managing symptoms such as fever, fatigue, and potential cytokine release syndrome, which can occur as the CAR-T cells become active in the body. Patients may also require supportive care to address any adverse reactions. The CAR-T cells are expected to remain active in the body for an extended period, providing ongoing surveillance against cancer recurrence. Follow-up appointments are essential to assess the effectiveness of the therapy and to monitor the patient's overall health and response to treatment.